伊鲁阿克(WX-0593)对比克唑替尼治疗ALK TKI初治的局部晚期或转移性ALK阳性非小细胞肺癌:随机、开放标签、3期研究(INSPIRE)的中期分析
该随机、开放标签、多中心3期研究在292例ALK TKI初治的局部晚期或转移性ALK阳性NSCLC患者中比较伊鲁阿克与克唑替尼,中期分析显示伊鲁阿克组经IRC评估的中位PFS显著长于克唑替尼组(27.7个月 vs 14.6个月,HR 0.34),颅内ORR在基线有可测量CNS转移患者中为90.9% vs 60.0%,3或4级治疗相关不良事件发生率两组相近(51.7% vs 49.7%)。
要点
- 伊鲁阿克组经IRC评估的中位PFS为27.7个月,克唑替尼组为14.6个月,HR 0.34(98.02%CI 0.23-0.52),p<0.0001。
- 经IRC评估的ORR伊鲁阿克组为93.0%,克唑替尼组为89.3%。
- 基线有可测量CNS转移患者的颅内ORR伊鲁阿克组为90.9%(10/11),克唑替尼组为60.0%(9/15)。
核心结论
- 伊鲁阿克较克唑替尼显著改善PFS并提高颅内抗肿瘤活性,可能成为晚期ALK阳性且ALK TKI初治NSCLC患者的新治疗选择。
研究设计与样本
- 开放标签、随机、多中心3期研究,患者随机接受伊鲁阿克180 mg每日一次(首7天60 mg每日一次导入)或克唑替尼250 mg每日两次。
- 2019年9月4日至2020年12月2日共292例患者随机并接受治疗,伊鲁阿克组143例,克唑替尼组149例。
- 主要终点为独立评审委员会(IRC)按RECIST 1.1评估的PFS,计划在IRC评估的192例预期PFS事件中约70%(134事件)时进行中期分析。
- 疗效在意向治疗人群分析,安全性在安全性人群(至少接受一剂研究药物的全部随机患者)分析。
主要发现
- 中期分析时(145事件),伊鲁阿克组中位随访26.7个月(范围3.7-37.7),克唑替尼组25.9个月(范围0.5-35.9)。
- IRC评估的中位PFS伊鲁阿克组为27.7个月(95%CI 26.3-不可估计),克唑替尼组为14.6个月(95%CI 11.1-16.5),HR 0.34(98.02%CI 0.23-0.52),p<0.0001。
- IRC评估的ORR伊鲁阿克组为93.0%(95%CI 87.5-96.6),克唑替尼组为89.3%(95%CI 83.1-93.7)。
- 基线有可测量CNS转移患者的颅内ORR伊鲁阿克组为90.9%(10/11,95%CI 58.7-99.8),克唑替尼组为60.0%(9/15,95%CI 32.3-83.7)。
- 3或4级治疗相关不良事件发生率伊鲁阿克组为51.7%,克唑替尼组为49.7%。
临床怎么用
- 原文结论指出伊鲁阿克可能成为晚期ALK阳性且ALK TKI初治NSCLC患者的新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Iruplinalkib (WX-0593) is a new-generation, potent ALK tyrosine kinase inhibitor (TKI) that has been found to have systemic and central nervous system (CNS) efficacy in ALK-positive NSCLC. We compared the efficacy and safety of iruplinalkib with crizotinib in patients with ALK TKI-naive, locally advanced or metastatic ALK-positive NSCLC. METHODS: In this open-label, randomized, multicenter, phase 3 study, patients with ALK-positive NSCLC were randomly assigned to receive iruplinalkib 180 mg once daily (7-d run-in at 60 mg once daily) or crizotinib 250 mg twice daily. The primary end point was progression-free survival (PFS) assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included PFS by investigator, objective response rate (ORR), time to response, duration of response, intracranial ORR and time to CNS progression by IRC and investigator, overall survival, and safety. An interim analysis was planned after approximately 70% (134 events) of all 192 expected PFS events assessed by IRC were observed. Efficacy was analyzed in the intention-to-treat population. Safety was assessed in the safety population, which included all randomized patients who received at least one dose of the study drugs. This study is registered with Center for Drug Evaluation of China National Medical Products Administration (CTR20191231) and Clinicaltrials.gov (NCT04632758). RESULTS: From September 4, 2019, to December 2, 2020, a total of 292 patients were randomized and treated; 143 with iruplinalkib and 149 with crizotinib. At this interim analysis (145 events), the median follow-up time was 26.7 months (range: 3.7-37.7) in the iruplinalkib group and 25.9 months (range: 0.5-35.9) in the crizotinib group. The PFS assessed by IRC was significantly longer among patients in the iruplinalkib group (median PFS, 27.7 mo [95% confidence interval (CI): 26.3-not estimable] versus 14.6 mo [95% CI: 11.1-16.5] in the crizotinib group; hazard ratio, 0.34 [98.02% CI: 0.23-0.52], p < 0.0001). The ORR assessed by IRC was 93.0% (95% CI: 87.5-96.6) in the iruplinalkib group and 89.3% (95% CI: 83.1-93.7) in the crizotinib group. The intracranial ORR was 90.9% (10 of 11, 95% CI: 58.7-99.8) in the iruplinalkib group and 60.0% (nine of 15, 95% CI: 32.3-83.7) in the crizotinib group for patients with measurable baseline CNS metastases. Incidence of grade 3 or 4 treatment-related adverse events was 51.7% in the iruplinalkib group and 49.7% in the crizotinib group. CONCLUSIONS: Iruplinalkib was found to have significantly improved PFS and improved intracranial antitumor activity versus crizotinib. Iruplinalkib may be a new treatment option for patients with advanced ALK-positive and ALK TKI-naive NSCLC. FUNDING: This study was funded by Qilu Pharmaceutical Co., Ltd., Jinan, People's Republic of China, and partly supported by the National Science and Technology Major Project for Key New Drug Development (2017ZX09304015).
引用
- Shi Y, Chen J, Yang R, et al. Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). J Thorac Oncol. 2024. PMID: 38280448. doi:10.1016/j.jtho.2024.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。